Table II.

Outcomes of de novo AML patients who cleared DNMT3A R882 mutations at CR and of those who did not.

End point	DNMT3A CR Group 1* (n = 14)	DNMT3A CR Group 2* (n = 42)	P	HR (95% CI)
Complete remission, n (%)	14 (100)	42 (100)	–	–
Disease-free survival
Median, years	0·6	11	0·52	1·26 (0·61–2·60)
% disease-free at 3 years (95% CI)	29 (9–52)	33 (20–48)
% disease-free at 5 years (95% CI)	29 (9–52)	31 (18–45)
Overall survival
Median, years	1·3	31	0·47	1·33 (0·62–2·83)
% alive at 3 years (95% CI)	36 (13–59)	50 (34–64)
% alive at 5 years (95% CI)	36 (13–59)	40 (25–54)

AML, acute myeloid leukaemia; CI, confidence interval; CR, complete remission; HR, hazard ratio; n, number.

^*Group 1 is defined as patients whose DNMT3A R882 mutation cleared below the VAF cut-off of 3% in their remission sample and who had no other AML mutation, and Group 2 is defined as patients with a DNMT3A R882 mutation with a VAF >3% with or without other AML mutations in their remission sample.